Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175727 | 0.76 | TSHR (0.59) | TSHRATMKDM4EMEN1KMT2A | |
| SCHEMBL6320584 | 0.74 | KDM4E (0.61) | TSHRATMKDM4EMEN1KMT2A | |
| SCHEMBL20098112 | 0.73 | KDM4E (0.56) | TSHRATMKDM4EMEN1KMT2A | |
| SCHEMBL22984859 | 0.73 | TSHR (0.56) | TSHRATMKDM4EMEN1KMT2A | |
| SCHEMBL20988040 | 0.73 | KDM4E (0.44) | TSHRATMKDM4EMEN1KMT2A | |
| SCHEMBL20372839 | 0.71 | KDM4E (0.61) | TSHRATMKDM4EMEN1KMT2A | |
| Hydroxyamine SCHEMBL7464955 | 0.71 | ALOX12 (0.46) | TSHRATMKDM4EMEN1KMT2A | |
| SCHEMBL1631053 | 0.70 | TSHR (0.65) | TSHRATMKDM4EMEN1KMT2A | |
| SCHEMBL21755154 | 0.70 | POLB (0.57) | KDM4EALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL21536752 | 0.70 | KDM4E (0.55) | TSHRATMKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |